---
title: "H1 results significantly exceeded expectations, WuXi AppTec dispels all doubts"
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/43177179.md"
description: ""WuXi AppTec will be number one in the world sooner or later." After releasing a half-year report that significantly exceeded expectations, market sentiment towards WuXi AppTec has reached a peak. On the evening of August 3, WuXi AppTec released its first half of 2026 report. The data shows that its H1 revenue was 28.897 billion yuan, a year-on-year increase of 38.93%; net profit attributable to shareholders was 11.08 billion yuan, a year-on-year increase of 29.43%. Adjusted non-IFRS net profit attributable to shareholders was 11.571 billion yuan, a year-on-year increase of 83.23%, with a constant-basis net profit margin of 40%..."
datetime: "2026-08-04T09:15:29.000Z"
locales:
  - [en](https://longbridge.com/en/topics/43177179.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/43177179.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/43177179.md)
author: "[松果财经Pinecone](https://longbridge.com/en/profiles/26955235.md)"
generator: "portal-rs"
---

# H1 results significantly exceeded expectations, WuXi AppTec dispels all doubts

"WuXi AppTec will be number one in the world sooner or later." After releasing a semi-annual report that significantly exceeded expectations, market sentiment towards WuXi AppTec has reached a peak.

In the evening of August 3, WuXi AppTec released its 2026 semi-annual report. Data shows that its revenue in the first half of the year was 28.897 billion yuan, a year-on-year increase of 38.93%; net profit attributable to shareholders was 11.08 billion yuan, a year-on-year increase of 29.43%. The adjusted non-IFRS net profit attributable to shareholders was 11.571 billion yuan, a year-on-year increase of 83.23%, with a net profit margin on a comparable basis of 40%, an increase of nearly 10 percentage points year-on-year.

What surprised the market even more was that management fully raised its full-year guidance. The revenue target was increased from a range of 51.3 billion to 53 billion yuan to 58.5 billion to 60.5 billion yuan in one go; the growth rate of revenue from continuing operations was revised from 18% to 22% to 35% to 39%; guidance for capital expenditures and free cash flow was also raised synchronously. Currently, its order backlog is 66.43 billion yuan, a year-on-year increase of 25.2%, which has already surpassed the midpoint of the new full-year guidance.

Are truly hardcore assets just stories, or are they orders, capacity, and cash flow? WuXi AppTec has both, and it is even awakening the imagination of the entire sector.

**I. The molecular funnel is turning, and what is more meaningful than cyclical recovery is the realization of the model**

WuXi AppTec's growth was within market estimates, but the market did not expect this situation.

In the first half of the year, its chemical business revenue was 24.99 billion yuan, a year-on-year increase of 53.3%; testing business was 2.48 billion yuan, up 31.5%; biological business was 1.39 billion yuan, up 11.2%. All three sectors showed positive growth, with acceleration quarter by quarter—Q2 single-quarter revenue was 16.46 billion yuan, a year-on-year growth of 47.7%, significantly faster than Q1's 28.8%.

As is well known, in the CRDMO business model, the R end (small molecule drug discovery) is responsible for drug discovery, while the D&M end (small molecule process R&D and production) is responsible for process development and commercial production. Early-stage R&D projects drive traffic to later-stage projects, and the ramp-up of later-stage projects in turn increases capacity utilization and profit margins.

In the first half of the year, WuXi AppTec successfully synthesized and delivered over 440,000 new compounds at the R end, and added 699 pipeline molecules at the D&M end, of which 155 D-end results came from internal conversion at the R end. There were 15 new high-value late-stage clinical phase III and commercialization projects. As of the end of the first half of the year, the small molecule D&M pipeline reached 3,731.

Rather than scale, conversion efficiency is the focus of market attention. The integrated platform helps customers' projects enter clinical trials one to two months or even longer in advance by reducing technical handovers, repeated verification, and communication coordination between different links. For innovative drugs, the patent window period is a lifeline; being two months early could mean hundreds of millions of dollars in market opportunities. The smoother the progress of customers' projects, the larger the downstream R&D and production demand, and the natural progression of the platform's performance growth follows.

In the first half of the year, WuXi AppTec underwent 465 quality reviews from global customers, regulatory agencies, and independent third parties, maintaining no serious findings throughout. The rigorous quality system running through the process provided assurance for the stable advancement of projects.

As projects continue to extend downstream, the conversion value of the CRDMO model begins to appear. Small molecule D&M business revenue surged 72.7% year-on-year to 14.99 billion yuan, serving as the core engine driving profit elasticity. TIDES new molecule businesses represented by peptides and oligonucleotides had a revenue of 7.26 billion yuan in the first half of the year, a year-on-year increase of 44.3%, with the number of service clients and service molecules increasing by 39% and 68% respectively, with an expected full-year increase of about 45%. On a revenue base of tens of billions of yuan, the profit margin continues to rise at a high level, which is rare in the industry.

WuXi AppTec maintained growth resilience even in the winter, and demonstrated acceleration far exceeding peers during the recovery. The root of the difference lies in the model, not the cycle.

**II. The competitive rules of the CXO industry have been rewritten; recovery is not universal**

If we expand the view from WuXi AppTec to the entire CXO industry, "differentiation" is inevitably the most important keyword.

On the surface, the industry is indeed recovering. In 2025, among 30 A-share medical R&D outsourcing enterprises, 25 had positive revenue growth and 22 had positive net profit growth; in Q1 2026, 24 had positive revenue growth and 20 had positive net profit growth. The scope of growth has not narrowed, indicating that the recovery is sustainable.

However, if we divide the CXO industry into three types of companies: those focusing on CRO, those focusing on CDMO, and integrated CXO companies laying out both R&D and production ends, then looking at the performance performance from this round of recovery, vertical CDMO enterprises generally achieved profit reversal through a dual-wheel drive of traditional businesses building a bottom line and emerging businesses breaking through, while integrated CXO leaders demonstrated stronger recovery resilience and growth certainty 凭借 their full-chain synergy advantages.

For example, Botong Shares, with a smaller market cap, once achieved the largest gain in the sector today.

In terms of performance, it turned a profit in 2025, with small molecule API business growing approximately 13% year-on-year, stabilizing the basic board; emerging business grew approximately 26% year-on-year, with a growth rate far exceeding the main business. In the first half of 2026, after excluding the impact of one-time asset impairment, non-GAAP net profit attributable to shareholders increased by 835% to 1302% year-on-year.

In addition, Asymchem, known as "twice long WuXi," is evolving from a small molecule CDMO leader to a full-process integrated CRO plus CDMO platform. In Q1 2026, its emerging business revenue soared 74.07% year-on-year. Pharmaron took another path, using a full industry chain layout to hedge against cyclical fluctuations in a single link, expecting H1 2026 revenue to grow 16% to 19% year-on-year, and adjusted net profit attributable to shareholders to grow 17% to 22%.

The recovery of single-track enterprises relies heavily on industry cycle beta, while enterprises with business breadth and new business reserves can better traverse cycles and achieve independent alpha returns. The root of differentiation is that the CXO industry faces a series of complex situations, such as increasingly complex structures of innovative drug molecules, pharmaceutical companies becoming more sensitive to the return on R&D investment, and budgets concentrating more on platforms that can stably advance projects and improve R&D efficiency.

In simple terms, the focus of industry competition has shifted from whether there is capacity to process accumulation, compliance systems, and global delivery capabilities.

In the CRO track, the performance of 昭衍新药 (Zooxall) previously indicated that leading enterprises with monkey reserves are enjoying cycle dividends 凭借 their resource monopoly advantages. Zooxall saw a significant decline in net profit in 2024 due to falling monkey prices, followed by a surge of 302.08% in net profit in 2025 when monkey prices rebounded. Non-GAAP net profit in H1 2026 is expected to grow 2334.2% to 3551.3%. Yinuosi signed contracts totaling 729 million yuan in Q1 2026, a year-on-year increase of 198.79%. Yakang Biology, as a more upstream model animal CRO, showed more resilient performance growth, with H1 2026 net profit attributable to shareholders expected to grow 46.67% to 60.78%.

Resources, technology, and integration capabilities are increasingly influencing market evaluation. This is also reflected in the dynamics of the capital market. Hillhouse Capital recently invested 177 million yuan to increase its stake in Asymchem BIO, a subsidiary of Asymchem. This is a Pre-IPO investment with a valuation adjustment mechanism (VAM), requiring a qualified IPO within four years, otherwise repurchased at an annualized simple interest rate of 8%. Asymchem BIO focuses on contract R&D and production of antibodies and ADCs. Among 27 Chinese pharmaceutical companies' ADC overseas projects, it provides CMC services for 21 of them.

Hillhouse disappeared collectively from the top ten shareholder lists of Asymchem, Tigermed, etc., in Q3 2021, and has now re-entered in a new way, indicating that capital's judgment logic for the CXO sector has shifted from secondary market valuation games to long-term bets on capacity and process barriers in niche tracks.

**III. Focus on the 博弈 factors behind high growth; valuation switch is complete**

Currently, the market basically has no worries about WuXi. If you must find a flaw, it is geopolitical factors: In 2025, the company's revenue from US customers was 31.25 billion yuan, a year-on-year increase of 34.3%, accounting for about 72% of the proportion of revenue from continuing operations. On June 8, 2026, the US Department of Defense listed WuXi AppTec as a relevant entity based on the 1260H list. However, the company filed a lawsuit in the US District Court for the District of Columbia on June 11, applying to revoke the determination and remove it from the relevant list.

Moreover, WuXi AppTec's response to such potential problems demonstrates the strategic resolve of management. The company is not passively waiting for policy clarity but is actively restructuring its asset portfolio. Over the past year, WuXi AppTec announced the sale of its US medical device testing business, selling two factories in Atlanta and Sao Paulo to NAMSA; it also sold its cell and gene therapy business in the US and UK under WuXi Biologics to Altaris, raising over 9 billion yuan in cumulative funds.

Last year, the company also sold Kangde Hongyi and WuXi Jinshi for 2.8 billion yuan, divesting the weaker profitability segments in domestic clinical CROs, while reasonably distributing new capacity globally.

This series of moves can basically be called "textbook" level: gradually exiting businesses with weak profitability, complex management, and dispersed regions, and concentrating resources on core sectors with high gross margins, strong growth potential, and global competitiveness. Over the past five years, WuXi AppTec has successfully shifted the main sources of revenue and profit to the production links of global pharmaceutical clients, comprehensively enhancing its strategic value.

During this process, WuXi AppTec's capital expenditures and operating cash flow have always remained balanced, with a strong sense of "discipline." In the first half of 2026, capital expenditures reached 2.96 billion yuan, and adjusted operating cash flow reached 9.98 billion yuan, both growing by approximately 41%, roughly in sync with revenue growth. WuXi AppTec, however, went the opposite way: while raising capital expenditures, the midpoint of its free cash flow guidance was instead raised by about 27%. Management's layout is not simply expanding the balance sheet, but betting on further releasing operating leverage after capacity ramp-up.

This is a positive signal, drawing market attention to overlooked opportunities in the biopharma track—it turns out there are still many high-quality enterprises that do not rely on Capex narratives exceeding norms or potentially collapsing to support development expectations, unlike the hot AI track.

In the first half of 2026, the total amount of global biopharmaceutical R&D licensing transaction announcements reached 166.7 billion USD, already exceeding half of the record level set in all of 2025; M&A transaction totals reached 96 billion USD; venture capital financing reached 16.3 billion USD, hitting a same-period high since 2023. China's pharmaceutical overseas transaction total amount reached 99.7 billion USD, 1.9 times the 52.2 billion USD of all of 2024.

Data from Frost & Sullivan shows that global pharmaceutical R&D total investment is expected to maintain a compound annual growth rate of 5% to 6%, and the pharmaceutical R&D outsourcing rate continues to rise. In the medium to long term, China's comparative advantage in drug discovery and clinical proof-of-concept stages is difficult to replace. Before the maturity of local pharmaceutical companies' autonomous globalization capabilities, BD overseas expansion may become normalized, and overseas licensing payments will continue to supplement R&D funds, steadily expanding domestic demand within the CXO industry.

This further opens up the market's imagination space for WuXi AppTec's interim report. A platform capable of traversing cycles and possessing scarcity deserves a re-pricing.

Source: Pine Finance

### Related Stocks

- [02359.HK](https://longbridge.com/en/quote/02359.HK.md)
- [300363.CN](https://longbridge.com/en/quote/300363.CN.md)
- [06821.HK](https://longbridge.com/en/quote/06821.HK.md)
- [03759.HK](https://longbridge.com/en/quote/03759.HK.md)
- [603259.CN](https://longbridge.com/en/quote/603259.CN.md)
- [002821.CN](https://longbridge.com/en/quote/002821.CN.md)
- [300759.CN](https://longbridge.com/en/quote/300759.CN.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**